{"version":"1.0","provider_name":"FYB Financial Yearbook","provider_url":"https:\/\/www.fyb.de\/en\/","author_name":"Tatjana Anderer","author_url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/","title":"SHS invests in Swiss life science company evitria - FYB Financial Yearbook","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"jBHFPy8rO0\"><a href=\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\">SHS invests in Swiss life science company evitria<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/embed\/#?secret=jBHFPy8rO0\" width=\"600\" height=\"338\" title=\"&#8220;SHS invests in Swiss life science company evitria&#8221; &#8212; FYB Financial Yearbook\" data-secret=\"jBHFPy8rO0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg","thumbnail_width":512,"thumbnail_height":512,"description":"T\u00fcbingen\/Schlieren (Switz\u00ader\u00adland) - SHS V, a fund mana\u00adged by T\u00fcbin\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment, is inves\u00adt\u00ading in Swiss evitria AG toge\u00adther with AFINUM. The life science company supplies large phar\u00admaceu\u00adti\u00adcal and biotech compa\u00adnies with custom anti\u00adbo\u00addies for rese\u00adarch. For SHS, it is the first invest\u00adment from the SHS V fund, which had its first closing [&hellip;]"}